The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Have You Heard

Sunday, 12 March 2017
For the first time the European Commission has approved the use of a diabetes treatment for its effect on both blood sugar and cardiovascular events. Empagliflozin product information now includes data on the reduction of risk of cardiovascular death in addition to data on the improvement of blood sugar control.
Category: Have You Heard
Topics covered:
Sunday, 12 March 2017
A new fixed dose combination of saxagliptin (Onglyza) and dapagliflozin (Forxiga) is now available for use in adults with type 2 diabetes.
Category: Have You Heard
Topics covered:
Sunday, 12 March 2017
A useful free infographic provides international data on cardiovascular drug adherence. Although the UK lags behind other European countries, it has better adherence rates than the USA, Australia and a number of South American countries.
Category: Have You Heard
Thursday, 02 February 2017
A practical down-to-earth manual on the whole range of long-term conditions has been written for UK general practice nurses by experts in their field. The book provides a quick way for new practice nurses to learn the basics about long-term conditions and will also be useful to the wider primary healthcare team.
Category: Have You Heard
Wednesday, 04 January 2017
A new report from the Royal College of Physicians (RCP) highlights a wide range of improvements needed in the management of chronic obstructive pulmonary disease (COPD) care in primary care in England.
Category: Have You Heard
Topics covered:
Wednesday, 04 January 2017
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending extension of the label for all metformin-containing products to included patients with stable moderate renal failure (chronic kidney disease stage 3).
Category: Have You Heard
Topics covered:
Wednesday, 04 January 2017
Dapagliflozin is now recommended by NICE as part of triple therapy with metformin and a sulfonylurea when two drugs for type 2 diabetes are not providing glycaemic control.
Category: Have You Heard
Topics covered:
Thursday, 20 October 2016
A new document from Public Health England (PHE) highlights the ongoing impact of cardiovascular disease (CVD), and provides an overview of PHEs work in CVD.
Category: Have You Heard
Topics covered:
Page 3 of 3

Article search and filter